Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | ALKBH3 | Q96Q83 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669226 | 0.85 | XIAP (0.32) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669094 | 0.83 | ALDH1A1 (0.33) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669200 | 0.81 | NPC1 (0.39) | HPGD | |
| SCHEMBL1672314 | 0.81 | CYP1A2 (0.33) | ADORA2ACYP3A4MEN1CYP1A2CYP2C9 | |
| SCHEMBL12198932 | 0.80 | CYP3A4 (0.31) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669100 | 0.80 | ALDH1A1 (0.33) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669470 | 0.79 | ALDH1A1 (0.37) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669183 | 0.75 | KDM5B (0.42) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1669954 | 0.75 | HDAC1 (0.40) | CYP3A4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL417504 | 0.72 | KCNH2 (0.51) | MEN1CYP2C9KMT2AKCNH2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | claimed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | claimed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | claimed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | claimed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245241-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ADORA2A 3512/4885TYMP 4/4885ALKBH3 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.